P183: Molecular characterisation of the remission mediated by CAR T cells in Systemic Lupus Erythematosus
FAU own research funding: EFI / IZKF / EAM ...
Start date : 01.01.2026
End date : 31.12.2026
Project details
Scientific Abstract
Despite progress in understanding SLE, remission is rare. A "treat-to-target" approach aims to minimize disease activity, reducing organ damage and flares. B-cell immunity transcriptional signature correlates with treatment response, with effective therapy requiring its reversal. CAR T cells show promise for sustained, drug-free remission. Here, we will delineate transcriptional fingerprints of treatment response and resistance to uncover molecular drivers of effective therapy and remission.
Involved:
Contributing FAU Organisations:
Interdisziplinäres Zentrum für Klinische Forschung (IZKF)
Department of Medicine 3 – Rheumatology and Immunology
